A Diagnostics & Imaging Week
Significantly expanding its East Coast presence, CoActiv (Ridgefield, Connecticut) reported an agreement with NY Imaging Service (Newburgh, New York) for the distribution of its Exam-PACS, Exam-Vault Quad-Redundant Archiving and related digital image management products throughout the New York and Northern New Jersey regions.
The distributor has already completed nine sales, many to women's health centers.
"CoActiv's Exam-PACS is packed with performance at a very affordable price. It truly is in a class by itself," said Bill Haussmann, CEO of NY Imaging. "There is no better proof than that we have been able to close so many sales in such a short time period. Customers are really drawn to all the advanced features and the reasonable price point."
NY Imaging also decided to partner with CoActiv because of the product line's flexible ability to support imaging centers, small hospitals and specialty practices, including orthopedic, chiropractic and veterinary practices.
"Traditionally, NY Imaging's client base has consisted of radiology clinics, many of which are just now going digital," he said. "However, the adaptability of the Exam-PACS solutions to scale from small clinics to major multi-site hospitals is opening new doorways for our business. Our hospital's joint installations with CoActiv (Sound Shore Medical Center and Mount Vernon Hospital), in addition to the broad customer types mentioned above, show how adaptable the CoActiv product is. Moreover, CoActiv's turnkey offsite archiving program will streamline the implementation and management of advanced primary and back up HIPAA compliant data storage."
In other agreements/contracts news:
• deCODE genetics (Reykjavik, Iceland) and Celera (Alameda, California) have signed agreements under which deCODE has granted Celera non-exclusive worldwide licenses to deCODE's genetic markers for increased risk of major cardiovascular and metabolic diseases, including heart attack, stroke, atrial fibrillation and type 2 diabetes. These markers can be incorporated into laboratory tests for assessing and managing individual risk of these diseases.
"This is an excellent opportunity to broaden the clinical application and commercialization of our discoveries of high-impact genetic risk factors for major diseases. The markers included in these agreements are among the most widely replicated genetic risk factors for cardiovascular and metabolic disease, and they provide a natural complement to the biomarker services already offered by Berkeley HeartLab, Celera's subsidiary. In Celera we have a partner with a global reputation in human genetics and a large and effective outreach and sales force. We are pleased to have the chance to work with them to build upon our discovery and testing platforms and to accelerate the adoption of personalized medicine," said Kari Stefansson CEO of deCODE.
• Magnet Cooperative (Atlanta), a non-profit group purchasing organizations, has signed a sole-source agreement with Elekta (Stockholm, Sweden), enabling its members to begin purchasing Elekta's oncology delivery systems.